Molecular genetic analysis of KRAS, NRAS, and BRAF genes was carried out in order to develop an optimal algorithm for detection of minor mutations. We analyzed 35 melanoma and 33 colorectal cancer specimens. Frequent G12D/V/A/C/S mutations were detected in KRAS. The most frequent BRAF mutation in melanoma was V600E, the percentage of rare mutations is significant for DNA diagnosis (24%). Identification of rare BRAF mutations 1790C→G (L597R), 1798_1799delinsAA (V600K), 1798_1799delinsAG (V600R), and 1799_1800delinsAA (V600E) and NRAS mutation 38G→T (G13V) was possible only by Sanger sequencing. The combination of real-time PCR and sequencing can improve analysis sensitivity and ensure concordance of the tested loci with the international recommendations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy: American society of clinical oncology provisional clinical opinion update 2015. J. Clin. Oncol. 2016;34(2):179-185.
Boleij A, Tops BB, Rombout PD, Dequeker EM, Ligtenberg MJ, van Krieken JH.; Dutch RAS EQA Initiative. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget. 2015;6(17):15 681-15 689.
De Stefano A, Carlomagno C. Beyond KRAS: predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J. Gastroenterol. 2014;20(29):9732-9743.
Fariña Sarasqueta A, Moerland E, de Bruyne H, de Graaf H, Vrancken T, van Lijnschoten G, van den Brule AJ. SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J. Mol. Diagn. 2011;13(2):199-205.
Lopes GL, Vattimo EF, de Castro Junior Gd. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. J. Bras. Pneumol. 2015;41(4):365-375.
Magliacane G, Grassini G, Bartocci P, Francaviglia I, Dal Cin E, Barbieri G, Arrigoni G, Pecciarini L, Doglioni C, Cangi MG. Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. Oncotarget. 2015;6(31):30 592-30 603.
Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 2012;18(12):3242-3249.
Muñoz-Couselo E, Garcia JS, Perez-Garcia JM, Cebrián VO, Castán JC. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann. Transl. Med. 2015;3(15):207.
Shan L, Li M, Ma J, Zhang H. PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis. PLoS ONE. 2014;9(9):e107926.
Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, Ottaviano V, Queirolo P. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015;8:157-168.
Stintzing S. Management of colorectal cancer. F1000 Prime Rep. 2014;6:108.
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014;25(Suppl. 3):iii1-iii9.
Zheng G, Tseng LH, Chen G, Haley L, Illei P, Gocke CD, Eshleman JR, Lin MT. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer. 2015;15:779.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 162, No. 9, pp. 362-365, September, 2016
Rights and permissions
About this article
Cite this article
Mikhailenko, D.S., Efremov, G.D., Safronova, N.Y. et al. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. Bull Exp Biol Med 162, 375–378 (2017). https://doi.org/10.1007/s10517-017-3619-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-017-3619-z